Convergence of Targeted Drugs With Genomics-Based Diagnostics to Create New Paradigm for Cancer Treatment

for Cancer Treatment Next-Generation Cancer Diagnostics Market to Grow 22% Annually Through 2025

March 19, 2021

Big Data is our greatest potential weapon in the fight against cancer. Despite countless advancements, cancer remains the second-leading cause of death worldwide, and the burden on patients, families and society is profound.

Advanced diagnostics for cancer represent a major market opportunity for life sciences companies, according to the BCC Research report, Next-Generation Cancer Diagnostics: Technologies and Global Markets.

Three pressing needs in cancer diagnostics loom large: The first is earlier stage identification, identifying cancer before it has spread to other parts of the body. The second is a more accurate classification of suspicious lesions or nodules. Thirdly, we need cancer diagnostics that guide therapy decisions.

Report Highlights

  • The global market for next-generation cancer diagnostics is expected to grow from $6.2 billion in 2020 to $16.7 billion by 2025 with a compound annual growth rate (CAGR) of 21.9%.
  • Next-generation breast cancer diagnostics is expected to grow from $1.6 billion in 2020 to $3.1 billion by 2025 with a CAGR of 13.9%.
  • Analysis of key market players: Abbott Laboratories, Thermo Fisher Scientific and Danaher Corp.

Explore the full report here:

Next Generation Cancer Diagnostics: Technologies and Global Markets( BIO081C )
Publish Date: Aug 2020    

Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. For media inquiries, email or visit to request access to our library of market research.